News & Presentations Filter by Category All 123 Company News 53 Media 26 Newsletter 9 Presentations & Webinars 37 Company News, All Michelle Long 9/9/26 Company News, All Michelle Long 9/9/26 Notification of 2026 AGM Read More Company News, All Michelle Long 7/9/26 Company News, All Michelle Long 7/9/26 Clinical manufacturing batch released, first site activated Read More Company News, All Michelle Long 25/6/26 Company News, All Michelle Long 25/6/26 First-in-human trial Read More Company News, All Michelle Long 9/6/26 Company News, All Michelle Long 9/6/26 Professor Cameron Turtle to Clinical Advisory Board and Dr Sam Fiorenza to Lead Investigator Read More Company News, All Michelle Long 7/5/26 Company News, All Michelle Long 7/5/26 Arovella presents at ISCT Dublin Read More Company News, All Michelle Long 7/5/26 Company News, All Michelle Long 7/5/26 Dr Nicole van der Weerden appointed acting CEO Read More Company News, All Michelle Long 4/5/26 Company News, All Michelle Long 4/5/26 Board refresh and CEO resignation Read More Company News, All Michelle Long 29/4/26 Company News, All Michelle Long 29/4/26 Appointment of Directors Read More Company News, All Michelle Long 20/4/26 Company News, All Michelle Long 20/4/26 Arovella presents poster at AACR Annual Meeting Read More Company News, All Michelle Long 15/4/26 Company News, All Michelle Long 15/4/26 Arovella receives additional R&D tax rebate of $0.28 million Read More Company News, All Michelle Long 1/4/26 Company News, All Michelle Long 1/4/26 CLDN18.2 CAR-iNKT cell preclinical data update Read More Company News, All Michelle Long 16/3/26 Company News, All Michelle Long 16/3/26 TGA clears ALA-101 trial under CTN scheme Read More Company News, All Michelle Long 9/2/26 Company News, All Michelle Long 9/2/26 Board Changes Read More Company News, All Michelle Long 5/2/26 Company News, All Michelle Long 5/2/26 Letter from Managing Director & CEO Read More Company News, All Michelle Long 29/1/26 Company News, All Michelle Long 29/1/26 Arovella’s IND for ALA-101 accepted by the U.S. Food and Drug Administration Read More Company News, All Michelle Long 30/12/25 Company News, All Michelle Long 30/12/25 Arovella files IND with the U.S. FDA for ALA-101 phase 1 clinical trial Read More Company News, All Michelle Long 12/11/25 Company News, All Michelle Long 12/11/25 Arovella appoints former CSL CSO Dr Andrew Nash as Non-executive Director Read More Company News, All Michelle Long 5/11/25 Company News, All Michelle Long 5/11/25 ALA exercises Option for Baylor College of Medicine assets Read More Company News, All Michelle Long 30/10/25 Company News, All Michelle Long 30/10/25 AGM 2025 presentation and results Read More Company News, All Michelle Long 29/10/25 Company News, All Michelle Long 29/10/25 Arovella progresses ALA-101 program with appointment of phase 1 CRO Read More Older Posts
Company News, All Michelle Long 9/9/26 Company News, All Michelle Long 9/9/26 Notification of 2026 AGM Read More
Company News, All Michelle Long 7/9/26 Company News, All Michelle Long 7/9/26 Clinical manufacturing batch released, first site activated Read More
Company News, All Michelle Long 25/6/26 Company News, All Michelle Long 25/6/26 First-in-human trial Read More
Company News, All Michelle Long 9/6/26 Company News, All Michelle Long 9/6/26 Professor Cameron Turtle to Clinical Advisory Board and Dr Sam Fiorenza to Lead Investigator Read More
Company News, All Michelle Long 7/5/26 Company News, All Michelle Long 7/5/26 Arovella presents at ISCT Dublin Read More
Company News, All Michelle Long 7/5/26 Company News, All Michelle Long 7/5/26 Dr Nicole van der Weerden appointed acting CEO Read More
Company News, All Michelle Long 4/5/26 Company News, All Michelle Long 4/5/26 Board refresh and CEO resignation Read More
Company News, All Michelle Long 29/4/26 Company News, All Michelle Long 29/4/26 Appointment of Directors Read More
Company News, All Michelle Long 20/4/26 Company News, All Michelle Long 20/4/26 Arovella presents poster at AACR Annual Meeting Read More
Company News, All Michelle Long 15/4/26 Company News, All Michelle Long 15/4/26 Arovella receives additional R&D tax rebate of $0.28 million Read More
Company News, All Michelle Long 1/4/26 Company News, All Michelle Long 1/4/26 CLDN18.2 CAR-iNKT cell preclinical data update Read More
Company News, All Michelle Long 16/3/26 Company News, All Michelle Long 16/3/26 TGA clears ALA-101 trial under CTN scheme Read More
Company News, All Michelle Long 9/2/26 Company News, All Michelle Long 9/2/26 Board Changes Read More
Company News, All Michelle Long 5/2/26 Company News, All Michelle Long 5/2/26 Letter from Managing Director & CEO Read More
Company News, All Michelle Long 29/1/26 Company News, All Michelle Long 29/1/26 Arovella’s IND for ALA-101 accepted by the U.S. Food and Drug Administration Read More
Company News, All Michelle Long 30/12/25 Company News, All Michelle Long 30/12/25 Arovella files IND with the U.S. FDA for ALA-101 phase 1 clinical trial Read More
Company News, All Michelle Long 12/11/25 Company News, All Michelle Long 12/11/25 Arovella appoints former CSL CSO Dr Andrew Nash as Non-executive Director Read More
Company News, All Michelle Long 5/11/25 Company News, All Michelle Long 5/11/25 ALA exercises Option for Baylor College of Medicine assets Read More
Company News, All Michelle Long 30/10/25 Company News, All Michelle Long 30/10/25 AGM 2025 presentation and results Read More
Company News, All Michelle Long 29/10/25 Company News, All Michelle Long 29/10/25 Arovella progresses ALA-101 program with appointment of phase 1 CRO Read More
